Ultragenyx药业 RARE 深 沪
已收盘 07-02 16:00:00 美东时间
33.47
+1.090
+3.37%
华盛通- 最 高33.50
- 今 开32.80
- 成交量 123.93万股
- 最 低 32.48
- 昨 收 32.38
- 总市值 32.96亿
- 52周最高 39.8899
- 市盈率 静 --
- 换手率 1.26%
- 52周最低 18.29
- 委 比 76.60%
- 总股本 9848.92万
- 历史最高 179.647
- 量 比 0.19
- 振 幅 3.15%
- 历史最低 18.29
- 每 手 1
- 风险率 4.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | Bloom Energy涨8.51%，Intuitive Machines涨6.69%
Bloom Energy涨8.51%；Intuitive Machines涨6.69%；SharonAI Holdings, Inc. Class A涨3.35%
07-01 09:01
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. granted 44,409 restricted stock units to 15 newly hired non-executive officers under its employment inducement plan, vesting over four years. The company focuses on developing therapies for rare and ultra-rare diseases with high unmet medical needs.
06-19 20:30
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today
U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps leading the tape, as investors held their fire ahead of Kevin Warsh‘s first interest-rate decision as Federal Reserve chair, due at 2 p.m. ET. The Fed is all but certain to hold the funds rate at 3.50%-3...
06-18 01:33
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of Jabil Inc (NYSE:JBL) rose sharply following upbeat quarterly earnings. Jabil reported quarterly earnings of $3.16 per share which beat the analyst consensus estimate of $3.10 per share. The com...
06-17 22:11
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. granted 17,567 restricted stock units to 11 newly hired non-executive officers, vesting over four years. The awards were approved under the Ultragenyx Employment Inducement Plan as inducements for new employees, in accordance with Nasdaq Listing Rule 5635(c)(4). The company focuses on developing therapies for rare and ultra-rare genetic diseases with high unmet medical needs.
05-22 20:30
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $96
Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $84 to $96.
05-21 22:22
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Guggenheim Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $43
Guggenheim analyst Debjit Chattopadhyay maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $52 to $43.
05-08 21:27
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
